2016 Participants
< Back

NAME: Amrita Valluri

Failure of a fracture to heal, or “non-union” is one of the most troubling and debilitating adverse outcomes in the field of orthopedics and can lead to prolonged disability and significantly increased health care costs. While every fracture carries some risk for non-union, systemic factors such as tobacco use, metabolic derangements, use of non-steroidal anti-inflammatory medications (NSAIDs), age, and local factors can influence fracture healing adversely. Human bone marrow (hBM) derived mesenchymal stem cells (hBM-MSCs) have been suggested as a suitable option for cell-based tissue engineering therapies. This is due to their capacity for self-renewal and their ability to differentiate into numerous different tissue types, such as bone, cartilage and fat.

In a classical approach, bone tissue engineering consists of harvesting bone marrow from a patient, isolating the hBM-MSCs by adherence to tissue culture plastic, expanding and differentiating them in culture and then seeding them onto a suitable synthetic scaffold prior to implantation into the same patient. Harvesting of cells from bone marrow is an invasive procedure, and additionally, stem cell numbers decrease significantly with the age of the individual. Therefore, the main purpose of this project is to develop novel tissue regeneration method to produce adequate quantities of mesenchymal stem cells (MSCs) to treat fractures and improve non-union treatments.

The expected outcomes for this research are: 1) to generate adequate hBM-MSCs bone graft material from needle aspirations of bone marrow and characterization of these cells before and after culture using flow cytometric assays and standardized surface markers as controls, and 2) to differentiate cultured hBM-MSCs into osteocytes and chondrocytes in the ex vivo environment by measuring the expression levels of specific markers by real-time PCR and flow cytometry.


To view their website click here: http://auvalluri.wixsite.com/sureproject